Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR1 | P30872 | 1/20 | 0.36 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.36 |
| ▸ | HTR1A | P08908 | 14/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 14/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 14/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 7/20 | 0.36 |
| ▸ | PLG | P00747 | 1/20 | 0.32 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30867708 | 0.81 | PLG (0.32) | PLG | |
| Hydrochloric Acid SCHEMBL30867700 | 0.73 | — | — | |
| SCHEMBL30867882 | 0.68 | HTR1A (0.36) | HTR1ASLC6A2SLC6A4SLC6A3 | |
| SCHEMBL11919643 | 0.66 | HTR2C (0.66) | HTR1ASLC6A2SLC6A4SLC6A3 | |
| SCHEMBL30867883 | 0.64 | TLR8 (0.33) | — | |
| SCHEMBL30867858 | 0.63 | HTR2A (0.31) | — | |
| SCHEMBL23868536 | 0.62 | PLG (0.41) | PLG | |
| SCHEMBL38653853 | 0.61 | PDE10A (0.34) | PLGPDE10A | |
| SCHEMBL23126514 | 0.60 | SLC6A2 (0.39) | SLC6A2 | |
| SCHEMBL16272028 | 0.60 | CHRNB2 (0.62) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260132143-A1 | HETEROCYCLIC INHIBITORS OF KRAS G12C MUTANT PROTEINS AND USES THEREOF | AMGEN INC. (US) | 2026-05-14 | — | — | US | disclosed |
| EP-4598917-A1 | HETEROCYCLIC INHIBITORS OF KRAS G12C MUTANT PROTEINS AND USES THEREOF | Amgen Inc. (US) | 2025-08-13 | — | — | EP | disclosed |
| WO-2024076674-A1 | HETEROCYCLIC INHIBITORS OF KRAS G12C MUTANT PROTEINS AND USES THEREOF | AMGEN INC. (US) | 2024-04-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260132143-A1 | HETEROCYCLIC INHIBITORS OF KRAS G12C MUTANT PROTEINS AND USES THEREOF | KRAS, NRAS, HRAS | SSTR1 1478/4885SSTR4 2922/4885HTR1A 4390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.